An open-label pilot study suggests that intravenous brexanolone may rapidly reduce psychotic, manic, and depressive symptoms in patients with postpartum psychosis, highlighting a potential new treatment option.
Women's Mental Health published a clinical update in Research Highlights on 31 Mar 2026.
The item focuses on Rapid Symptom Relief in Postpartum Psychosis with Brexanolone.
Review the original article for the full source wording and details.